Design of a multi-epitope vaccine candidate of gastric cancer against Helicobacter pylori
Abstract Background: Gastric cancer and peptic ulcers can both be caused by Helicobacter pylori (H. pylori). So the complexity of such bacterium made it difficult to develop an effective treatment. Thus, a computational approach to developing antigenicity, stability, and safety in vaccines against this pathogen will aid in the management of related diseases. Methods: This investigation chose two H. pylori proteins, SabA and BabA, as epitope prediction targets. Therefore, this study used an immunoinformatics platform to create a subunit vaccine against H. pylori. The best helper T lymphocytes (HTLs) along with cytotoxic T lymphocytes (CTLs) epitopes have been chosen according to antigenicity, toxicity and allergenicity. The chosen epitopes, suitable linkers, as well as adjuvants were combined for creating a final vaccine design. The antigenicity, allergenicity, along with physicochemical traits of vaccine were assessed. Results: The vaccine’s 3D structure has been anticipated. Molecular docking analysis along with molecular dynamics (MD) simulation were performed on multi-epitope vaccine. The vaccine candidate was in silico cloned in pET28a (+) vector. Conclusion: The results showed that final vaccine design would work well as an effective prophylactic vaccine versus H. pylori. To evaluate vaccine efficacy against the aforementioned bacteria, in vivo and in vitro trials are required..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ResearchSquare.com - (2023) vom: 06. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shojaeian, Ali [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-3364830/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA041004272 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA041004272 | ||
| 003 | DE-627 | ||
| 005 | 20231107130430.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231002s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-3364830/v1 |2 doi | |
| 035 | |a (DE-627)XRA041004272 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-3364830/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shojaeian, Ali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Design of a multi-epitope vaccine candidate of gastric cancer against Helicobacter pylori |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background: Gastric cancer and peptic ulcers can both be caused by Helicobacter pylori (H. pylori). So the complexity of such bacterium made it difficult to develop an effective treatment. Thus, a computational approach to developing antigenicity, stability, and safety in vaccines against this pathogen will aid in the management of related diseases. Methods: This investigation chose two H. pylori proteins, SabA and BabA, as epitope prediction targets. Therefore, this study used an immunoinformatics platform to create a subunit vaccine against H. pylori. The best helper T lymphocytes (HTLs) along with cytotoxic T lymphocytes (CTLs) epitopes have been chosen according to antigenicity, toxicity and allergenicity. The chosen epitopes, suitable linkers, as well as adjuvants were combined for creating a final vaccine design. The antigenicity, allergenicity, along with physicochemical traits of vaccine were assessed. Results: The vaccine’s 3D structure has been anticipated. Molecular docking analysis along with molecular dynamics (MD) simulation were performed on multi-epitope vaccine. The vaccine candidate was in silico cloned in pET28a (+) vector. Conclusion: The results showed that final vaccine design would work well as an effective prophylactic vaccine versus H. pylori. To evaluate vaccine efficacy against the aforementioned bacteria, in vivo and in vitro trials are required. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Sanami, Samira |4 aut | |
| 700 | 1 | |a Mahmoudvand, Shahab |4 aut | |
| 700 | 1 | |a Amini, Razieh |4 aut | |
| 700 | 1 | |a Alibakhshi, Abbas |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2023) vom: 06. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:06 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-3364830/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 06 |c 11 | ||